Scienture Holdings, Inc. (SCNX)
Official siteHEALTHCARE • PHARMACEUTICAL RETAILERS • NASDAQ
Market Cap: $4.91M
Last updated: Nov 17, 2026 at 4:10 PM ET
Scienture Holdings, Inc. (SCNX) Statistics
Scienture Holdings (SCNX) has a market cap of $4.91M and an enterprise value of $10.99M. It kept -2715.93% of revenue as net income over the last 12 months. Its share count is up 110.62% from a year earlier.
Total Valuation
Enterprise value is 123.77% above the market cap, as debt exceeds cash.
| Market Cap | $4.91M |
|---|---|
| Enterprise Value | $10.99M |
| Latest price (Nov 17, 2026) | $2.78 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 11, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 3.0x. Its year-end P/S ranged from 6.7x to 369.8x from 2019 to 2025.
| P/S Ratio | 3.0x |
|---|---|
| Forward P/S | 1.3x |
Price Statistics
The stock is down 82.72% over 52 weeks and trades 41.23% below its 50-day average.
| Beta (1Y) | 1.68 |
|---|---|
| 52-Week Change | -82.72% |
| 1-Month Change | -4.79% |
| 3-Month Change | -76.55% |
| 6-Month Change | -71.49% |
| 5-Year Change | -99.80% |
| 10-Year Change | -99.78% |
| Total Return (1Y) | -82.72% |
| Total Return (3Y CAGR) | -66.49% |
| Total Return (5Y CAGR) | -66.78% |
| Return vs SPY (1Y) | -93.84% |
| Max Drawdown (1Y) | -82.99% |
| Max Drawdown (3Y) | -99.46% |
| Sharpe Ratio (1Y) | -1.69 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $4.73 |
| 200-Day Average | $8.63 |
| 52-Week Range | $2.64 to $18.75 |
| RSI (14 Days) | 30.7 |
| Average Volume (20 Days) | 25.74K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.10x current liabilities, and total debt is 0.18x shareholder equity.
| Current Ratio | 1.10x |
|---|---|
| Quick Ratio | 0.97x |
| Debt / Equity | 0.18x |
| Interest Coverage | -25.00x |
Returns and Efficiency
Return on invested capital is -56.16% and return on equity is -68.70% over the last 12 months.
| Return on Equity (ROE) | -68.70% |
|---|---|
| Return on Assets (ROA) | -46.29% |
| Return on Invested Capital (ROIC) | -56.16% |
| Return on Capital Employed (ROCE) | -51.82% |
| ROA (5Y Average) | -76.12% |
| Asset Turnover | 0.02x |
| Inventory Turnover | 0.53x |
| Receivables Turnover | 1.14x |
| Cash Conversion Cycle | -1880 days |
Scores
SCNX has an Altman Z-Score of -2.92, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.92 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $1.49M over the last 12 months is up 127.40% from the 12 months before.
| Revenue | $1.49M |
|---|---|
| Revenue Growth (YoY) | +127.40% |
| Gross Profit | $1.17M |
| Operating Income | -$41.43M |
| Pretax Income | -$42.35M |
| Net Income | -$40.35M |
| EBITDA | -$38.51M |
| EBIT | -$41.00M |
| Reported EPS (TTM) | -$5.03 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 67.38% of the $87.18M in total assets.
| Cash and Equivalents | $4.75M |
|---|---|
| Total Debt | $10.83M |
| Net Debt | $6.08M |
| Net Debt Per Share | $3.81 |
| Working Capital | $772.60K |
| Shareholder Equity | $58.74M |
| Book Value Per Share | $36.78 |
| Tangible Book Value | -$10.87M |
| Total Assets | $87.18M |
| Total Liabilities | $28.44M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$14.69M |
|---|---|
| FCF Per Share | -$8.94 |
| Depreciation and Amortization | $2.49M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2788.53%.
| Gross Margin | 78.46% |
|---|---|
| Operating Margin | -2788.53% |
| Pretax Margin | -2850.19% |
| Net Margin | -2715.93% |
| EBITDA Margin | -2591.63% |
| EBIT Margin | -2759.31% |
| Gross Margin (5Y Average) | 37.33% |
Growth
Revenue fell 65.21% a year over 3 years.
| Revenue Growth (3Y CAGR) | -65.21% |
|---|---|
| Revenue Growth (5Y CAGR) | -52.10% |
| Book Value Per Share Growth (2Y CAGR) | +41.10% |
Dividends and Yields
SCNX does not pay a dividend.
| Buyback Yield | -334.75% |
|---|---|
| Shareholder Yield | -334.75% |
Stock Splits
The last split was a 1-for-25 reverse split on Oct 5, 2026.
| Last Split Date | Oct 5, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Peer Position
Against 4 similar companies, SCNX has the 2nd highest P/S.
P/S RatioPeer median 1.4x
ROICPeer median -32.90%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -98.74%
| P/S Ratio | 3.0x vs 1.4x median |
|---|---|
| ROIC | -56.16% vs -32.90% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +127.40% vs -98.74% median |
Analyst Forecast
Consensus estimates put revenue growth at 498.71% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +498.71% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SCNX
What is SCNX's market cap?
Scienture Holdings has a market cap of $4.91M. Its enterprise value, which adds debt and subtracts cash, is $10.99M.
How many shares of SCNX are outstanding?
Scienture Holdings has 1.60M shares outstanding. The count is up 110.62% from a year earlier.
Does SCNX pay a dividend?
No. Scienture Holdings does not pay a dividend.
How much debt does SCNX have?
Scienture Holdings has $10.83M of total debt and $4.75M of cash and equivalents, a net debt position of $6.08M.
SCNX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors